Strategic positioning Infraredx operates at the intersection of IVUS and NIRS imaging with FDA-cleared capabilities to identify high-risk lipid core plaques, presenting a compelling opportunity to expand into high-risk cardiology centers and imaging labs seeking advanced plaque characterization.

Growth through partnerships Recent collaborations with B. Braun Interventional Systems for FDA IDE trials and the Nipro portfolio integration indicate a channel-driven sales strategy; leverage these partnerships to access broader hospital networks, distributors, and interventional suites.

Global market Wins Successful launch of Makoto and Dualpro systems in Japan and the US market showcases international demand for intravascular imaging; target high-volume cardiology centers and export-oriented distributors in Europe and APAC.

Product family leverage Expanded hardware accessories such as the OKAY II Y-Connector complement imaging systems and can be bundled with Makoto and Dualpro deployments, offering add-on revenue opportunities and reduction in procedural blood loss for users.

Financial foothold With a revenue range of 10–25 million and a funding base of 25 million, Infraredx demonstrates investor confidence and potential for accelerated growth; present ROI-focused value propositions highlighting improved diagnostic accuracy and potential MACE risk stratification to drive capital equipment cycles.